Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacytidine + Valproic Acid vs Low-Dose Ara-C in AML/MDS
NCT00382590Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2005
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azacitidine and valproic acid in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Number of Participants With Response at 24 weeks and Event Free Survival. Started Aug 2005; status: completed.
02
Drugs
azacitidinevalproic acid
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00382590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382590.